Context Therapeutics

Context Therapeutics EBITDA per Employee

The EBITDA per Employee of Context Therapeutics (CNTX) as of Nov 18, 2026 is -2.65 M USD. In the previous year, EBITDA per Employee was -1.99 M USD — a change of 32.68% (lower).

EBITDA per Employee

-2.65 MUSD

YoY

32.68%

Last updated:

EBITDA per Employee of Context Therapeutics is 2025 -2.65 M USD. EBITDA per Employee of Context Therapeutics was 2024 -1.99 M USD. It decreases by 32.68% lower compared to the previous year.

The Context Therapeutics EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2017
-1.60 M USD
Jan 1, 2019
-358,476.27 USD
Jan 1, 2020
-171,477.87 USD
Jan 1, 2021
-701,721.27 USD
Jan 1, 2022
-1.03 M USD
Jan 1, 2023
-1.67 M USD
Jan 1, 2024
-1.99 M USD
Jan 1, 2025
-2.65 M USD
The Context Therapeutics EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-2.65 MUSD+32.68%
-1.99 MUSD+19.35%
-1.67 MUSD+63.01%
-1.03 MUSD+46.13%
-701,721.27USD+309.22%
-171,477.87USD-52.16%
-358,476.27USD-77.65%
-1.60 MUSD-27.61%
-2.22 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Context Therapeutics Stock analysis

What does Context Therapeutics do? Context Therapeutics, Inc. develops CTIM-76, a selective Claudin 6 x CD3 bispecific antibody targeting CLDN6-positive tumors. The company focuses on ovarian, lung, and testicular cancers where CLDN6 is expressed on tumor cells. CTIM-76 redirects T-cell-mediated lysis toward malignant cells by binding to Claudin 6 on tumors and activating CD3 on T cells only upon tumor engagement. The firm is a clinical-stage biopharmaceutical company with 9 full-time employees and an IPO in 2021. The company's primary product, CTIM-76, is designed for CLDN6-positive solid tumors including ovarian, lung, and testicular cancers. It operates as a clinical-stage biopharmaceutical firm without commercial products yet, relying on preclinical development for its bispecific antibody. The target market consists of patients with CLDN6-expressing tumors who may benefit from this targeted therapy. Context Therapeutics' revenue model is not disclosed in the provided business description. The company is focused on advancing CTIM-76 through clinical development for potential future commercialization. As a clinical-stage biopharmaceutical company, it likely generates funding through equity financing, research grants, or partnerships, but these are not specified in the description. Context Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Context Therapeutics stock

EBITDA per Employee of Context Therapeutics is -2.65 M USD in 2025.

EBITDA per Employee of Context Therapeutics changed from -1.99 M USD to -2.65 M USD, representing a 32.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Context Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Context Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Context Therapeutics

All Key Metrics — Context Therapeutics